Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy

mTORC1 inhibitor

cMET

The cell lysates were put through Western blot analysis for the detection of pPI3K, pAkt, pERK, PI3K, Akt, and ERK using the relevant antibodies

The cell lysates were put through Western blot analysis for the detection of pPI3K, pAkt, pERK, PI3K, Akt, and ERK using the relevant antibodies. the

June 29, 2022 by racetab4 Min Reading

cMET

Particularly we’ve tested equiactive molar ratios between 2 drugs in various sequences of administration (RAD for 48?cLC and h for 72?h (CLCRAD) or RAD for 72?cLC and h for 48?h (RADCLC) and in co-administration for 72?h

Particularly we’ve tested equiactive molar ratios between 2 drugs in various sequences of administration (RAD for 48?cLC and h for 72?h (CLCRAD) or RAD for

September 20, 2021 by racetab4 Min Reading

cMET

﻿The cell lysates were put through Western blot analysis for the detection of pPI3K, pAkt, pERK, PI3K, Akt, and ERK using the relevant antibodies

﻿Particularly we’ve tested equiactive molar ratios between 2 drugs in various sequences of administration (RAD for 48?cLC and h for 72?h (CLCRAD) or RAD for 72?cLC and h for 48?h (RADCLC) and in co-administration for 72?h

The cell lysates were put through Western blot analysis for the detection of pPI3K, pAkt, pERK, PI3K, Akt, and ERK using the relevant antibodies

Particularly we’ve tested equiactive molar ratios between 2 drugs in various sequences of administration (RAD for 48?cLC and h for 72?h (CLCRAD) or RAD for 72?cLC and h for 48?h (RADCLC) and in co-administration for 72?h